A key step for Qualigen Therapeutics’ QN-302

8 November 2023

Test tubes

Clinical stage therapeutics company, Qualigen Therapeutics has recently announced that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors.

The QN-302 therapeutic was discovered in UCL’s School of Pharmacy by Prof. Stephen Neidle’s team and exclusively licensed by Qualigen in January 2022. It works by selectively stabilising G4 complexes prevalent in the promoter region of oncogenes in many tumor types, impeding transcription of G4-containing cancer genes, and may potentially offer a tumor-agnostic clinical approach to treatment.

Earlier this year, Qualigen received Orphan Drug Designation for QN-302 and US FDA clearance to initiate a Phase 1 clinical trial.

Further information:

Read the news update from Qualigen Therapeutics

Qualigen Therapeutics case study